文献速递肝病

美国COVID-19大流行前后慢性肝病病因别死亡率趋势

Trends in Etiology-based Mortality From Chronic Liver Disease Before and During COVID-19 Pandemic in the United States.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-07-08

基于美国2017—2020年全国死亡记录的人群分析显示,COVID-19大流行期间酒精相关肝病(ALD)全因年龄标化死亡率季度增幅从大流行前的1.1%加速至11.2%,非酒精性脂肪性肝病从1.9%加速至6.6%;病毒性肝炎死亡率在大流行前显著下降后趋于平稳,因该人群中COVID-19相关死亡增加。

要点

  • COVID-19期间ALD全因死亡率季度增幅达11.2%,高于大流行前的1.1%。
  • 非酒精性脂肪性肝病死亡率季度增幅由1.9%加速至6.6%。
  • 病毒性肝炎死亡率大流行前显著下降,大流行期间因COVID-19相关死亡增加而趋于平稳。

核心结论

  • 与COVID-19前相比,ALD和非酒精性脂肪性肝病的全因死亡率在COVID-19大流行期间快速加速。
  • 病毒性肝炎死亡率显著下降,但该人群中COVID相关死亡显著增加。

研究设计与样本

  • 基于美国全国死亡记录(2017—2020年)的人群分析。
  • 采用joinpoint分析估计季度年龄标化死亡率的趋势及季度百分比变化(QPC)。

主要发现

  • ALD全因年龄标化死亡率在COVID-19大流行前以季度1.1%的速率上升,大流行期间以季度11.2%的速率急剧上升。
  • 非酒精性脂肪性肝病死亡率在大流行前稳步上升(QPC 1.9%),大流行期间加速(QPC 6.6%)。
  • 大流行期间ALD相关死亡率较病毒性肝炎相关死亡率陡增,但ALD个体中COVID-19所致死亡比例最低,为2.5%,比病毒性肝炎低50%以上。
  • 病毒性肝炎全因死亡率在大流行前显著下降,大流行期间因该人群中COVID-19相关死亡增加而趋于平稳。
  • 肝硬化死亡率在大流行期间明显上升,主要归因于ALD。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: During the global coronavirus disease 2019 (COVID-19) pandemic, patients with pre-existing chronic liver disease may represent a vulnerable population. We studied the etiology-based temporal trends in mortality of chronic liver disease and the underlying cause of death in the United States before and during the COVID-19 pandemic. METHODS: Population-based analyses were performed on United States national mortality records (2017-2020). Temporal trends in quarterly age-standardized mortality were obtained by joinpoint analysis with estimates of quarterly percentage change (QPC). RESULTS: Quarterly age-standardized all-cause mortality due to alcohol-related liver disease (ALD) initially increased at a quarterly rate of 1.1% before the COVID-19 pandemic, followed by a sharp increase during the COVID-19 pandemic at a quarterly rate of 11.2%. Likewise, steady increase in mortality of nonalcoholic fatty liver disease before the COVID-19 pandemic (QPC, 1.9%) accelerated during the COVID-19 pandemic (QPC, 6.6%). Although ALD-related mortality increased steeply compared with viral hepatitis-related mortality during the COVID-19 pandemic, the proportion of mortality due to COVID-19 among individuals with ALD was the lowest at 2.5%; more than 50% lower than viral hepatitis. The significant decline in all-cause mortality due to viral hepatitis before the COVID-19 pandemic plateaued during the COVID-19 pandemic due to increase in COVID-19-related mortality in individuals with viral hepatitis. Mortality due to cirrhosis increased markedly during the COVID-19 pandemic, mainly attributable to ALD. CONCLUSION: All-cause mortality for ALD and nonalcoholic fatty liver disease rapidly accelerated during the COVID-19 pandemic compared with the pre-COVID-19 era. There has been a significant decline in viral hepatitis; however, a significant increase in COVID-related death in this population.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kim D, Alshuwaykh O, Dennis BB, et al. Trends in Etiology-based Mortality From Chronic Liver Disease Before and During COVID-19 Pandemic in the United States. Clin Gastroenterol Hepatol. 2022. PMID: 35811045. doi:10.1016/j.cgh.2022.05.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。